General Information

The Retina Institute participates in numerous national studies recognizing that medical research lies at the core of clinical advancements. These studies are used to assist in the diagnosis, prevention and treatment of various retinal diseases. Clinical trials help establish if new treatments, new drugs, or new surgical procedures are safe and effective.

Participation in a clinical trial is an important decision and should be discussed with a physician. Enrollment in a study possibly means receiving the newest management and care for a disease or illness. Participants often join to help others with the same condition by assisting researchers in their efforts to find better treatments. These trials offer future hope for many people with sight-threatening conditions.

Clinical trials in the U.S. must follow strict protocol and be registered with The National Institute of Health (NIH). A listing of these studies can be found in the clinicaltrials.gov database.

  • ATMO-SPHERE

Pathology: Pseudophakic with nAMD

Description: A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD

  • l BP41670 BURGUNDY PART 3

Pathology: nAMD

Descriptin: A three-part, phase I/II study to investigate the safety, tolerability, pharmacokinetics, and efficacy of Zifibancimig following intraviteral adminstration of multiple ascending doses and continuous delivery from the port delivery in patients with neovascular age-related macular degeneration (Burgundy)

  • DRCR AF

Pathology: Non-Proliferative Diabetic Retinopathy (NPDR)

Description: A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening

  • DRCR AL

Pathology: Radiation Retinopathy

Description: A Randomized Clinical Trial Evaluating Anti-VEGF vs Sustained-Release Corticosteroid vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy.

  • DRCR AM

Pathology: ERM

Description: Randomized Trial Comparing Immediate versus Deferred Surgery for Symptomatic Epiretinal Membranes

  • DRCR AN

Pathology: Diabetic Macular Edema (DME)

Description: A Phase 2 Study Evaluating Short-Term Efficacy of Tonabersat (Xiflam) for Diabetic Macular Edema (DME).

  • DRCR AO

Pathology: Wet Age-Related Macular Degeneration (AMD)

Description: Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD.

  • JANSSEN GENE THERAPY TRIAL

Pathology: Geographic Atrophy (GA)

Description: A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NHOR (Natural History Observation Registry)

Pathology: Macular Telangiectasia type 2 (MacTel 2)

Description: World-wide registry of individuals with Macular Telangiectasia type 2, and their family members. in the registry involves an initial clinic visit with a comprehensive eye exam, and blood is drawn for MacTel research.

  • OCU410-101

Pathology: Geographic Atrophy

Description: A phase 1/2 study to assess the safety and efficacy of OCU410 for geographic atrophy secondary to dry age-related macular degeneration

  • OCULIS STAGE 2

Pathology: 20/50 or worse DME

Description: A Phase 2/3 Double-masked, Randomized, 2 stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema

  • OTX-TKI-2023-AMD-301

Pathology: Tx naïve nAMD

Description: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration